What Is Ironwood Pharmaceuticals, Inc. (IRWD) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Ironwood Pharmaceuticals, Inc.'s intrinsic value is estimated at a composite fair value of $8.13. While the stock appears modestly undervalued at $4.21 (implied upside of +93.2%), our analysis suggests a thinner margin of safety across 7 of 12 bullish models. Notably, Bayesian DCF sees the most upside at +428.3% (fair value: $22.24), while Dynamic NAV is the most conservative at -91.6% ($0.35). The spread between these extremes — +519.9% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About IRWD?
12 of 13 models are currently active for IRWD. Of these, 7 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates IRWD's intrinsic value at $22.24, implying +428.3% upside from the current price. See which stocks rank higher →
How Does IRWD Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, IRWD ranks #27 by Quality of Company score. CirclFi's QOC score of 8.4/10 evaluates 32 fundamental signals. A score of 8.4 places IRWD in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Ironwood Pharmaceuticals, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is IRWD a Value Trap?
CirclFi's Value Trap algorithm assigns IRWD a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Ironwood Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Ironwood Pharmaceuticals, Inc. scores 8.4 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +519.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IRWD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IRWD's 12 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad